{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:42:57Z","timestamp":1783334577580,"version":"3.54.6"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":549,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Recently, liver transplantation (LT) has been increasingly performed for unresectable hepatoblastoma (HB) with acceptable results. We conducted a national survey of cases undergoing living donor liver transplantation (LDLT) for HB to evaluate their outcomes. Thirty-nine patients (28 males and 11 females with a median age at LDLT of 3.6 years) who had undergone LDLT for HB by the end of 2009 were enrolled in this study. The clinical data were collected from their medical records via a questionnaire survey in 2011 (median follow-up = 4.6 years). Thirteen patients (33.3%) had extrahepatic lesions before LDLT. Thirty-eight patients (97.4%) received chemotherapy, and 15 (38.5%) underwent hepatectomy before LDLT. Twenty-seven patients (69.2%) were alive without recurrence after LDLT, and 12 patients (30.8%) suffered from recurrence. The most common site of recurrence was the lung (9 cases), which was followed by the graft liver (6 cases). The median interval from LDLT to recurrence was 5.5 months. Four of the 9 cases (44.4%) with lung metastasis underwent surgical resection, and 3 were alive without any tumor recurrence. Eight patients died because of tumor recurrence. The multivariate landmark analysis revealed that the independent recurrence risk factors were a high alpha-fetoprotein (AFP) level at diagnosis [\u2265500,000 ng\/mL; hazard ratio (HR) = 7.86, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.010], the presence of extrahepatic lesions before LDLT (HR = 3.82, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.042), and a high AFP level at LDLT (\u22654000 ng\/mL; HR = 9.19, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.036). The actuarial 3- and 5-year patient survival rates were 84.3% and 77.3%, respectively. In conclusion, with appropriate timing for scheduled LT, LDLT provides a valuable alternative treatment with excellent results for children with HB. <jats:italic toggle=\"yes\">Liver Transpl 20:333-346, 2014<\/jats:italic>. \u00a9 2013 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.23803","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T07:51:41Z","timestamp":1385711501000},"page":"333-346","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan"],"prefix":"10.1097","volume":"20","author":[{"given":"Seisuke","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mureo","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Umeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Uemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20250124","doi-asserted-by":"crossref","first-page":"416432","DOI":"10.1002\/cncr.23169","article-title":"Trends in childhood cancer incidence in the U.S. (19922004).","volume":"112","author":"Linabery","year":"2008","journal-title":"Cancer"},{"key":"R2-11-20250124","doi-asserted-by":"crossref","first-page":"741746","DOI":"10.1111\/hpb.12112","article-title":"Predictors of survival and incidence of hepatoblastoma in the paediatric population.","volume":"15","author":"Allan","year":"2013","journal-title":"HPB (Oxford)"},{"key":"R3-11-20250124","doi-asserted-by":"crossref","first-page":"10131018","DOI":"10.1002\/pbc.22893","article-title":"Critical review of controversial issues in the management of advanced pediatric liver tumors.","volume":"56","author":"Gupta","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R4-11-20250124","doi-asserted-by":"crossref","first-page":"12701275","DOI":"10.1002\/pbc.23301","article-title":"Initial liver transplantation for unresectable hepatoblastoma after chemotherapy.","volume":"57","author":"Hery","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R6-11-20250124","doi-asserted-by":"crossref","first-page":"800808","DOI":"10.1002\/pbc.24220","article-title":"Surgical treatment of hepatoblastoma.","volume":"59","author":"Meyers","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R7-11-20250124","doi-asserted-by":"crossref","first-page":"8291","DOI":"10.1097\/00000658-199301000-00014","article-title":"Surgical techniques and innovations in living related liver transplantation.","volume":"217","author":"Tanaka","year":"1993","journal-title":"Ann Surg"},{"key":"R8-11-20250124","doi-asserted-by":"crossref","first-page":"22292235","DOI":"10.1111\/j.1600-6143.2005.01003.x","article-title":"Livingdonor liver transplantation for hepatoblastoma.","volume":"5","author":"Kasahara","year":"2005","journal-title":"Am J Transplant"},{"key":"R9-11-20250124","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00383-010-2708-0","article-title":"Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol2: report from the JPLT.","volume":"27","author":"Hishiki","year":"2011","journal-title":"Pediatr Surg Int"},{"key":"R12-11-20250124","doi-asserted-by":"crossref","first-page":"547553","DOI":"10.1097\/00000658-199211000-00004","article-title":"An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors.","volume":"216","author":"Ozawa","year":"1992","journal-title":"Ann Surg"},{"key":"R13-11-20250124","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.1097\/00007890-200107150-00019","article-title":"Longterm results of livingrelated donor liver graft transplantation: a singlecenter analysis of 110 transplants.","volume":"72","author":"Hashikura","year":"2001","journal-title":"Transplantation"},{"key":"R14-11-20250124","doi-asserted-by":"crossref","first-page":"403411","DOI":"10.1097\/01.TP.0000110295.88926.5C","article-title":"Impact of recipient age on outcome of ABOincompatible livingdonor liver transplantation.","volume":"77","author":"Egawa","year":"2004","journal-title":"Transplantation"},{"key":"R15-11-20250124","first-page":"792799","article-title":"Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel.","volume":"31","author":"Demetris","year":"2000","journal-title":"Hepatology"},{"key":"R16-11-20250124","doi-asserted-by":"crossref","first-page":"361387","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"R17-11-20250124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1472-6947-6-41","article-title":"Polychotomization of continuous variables in regression models based on the overall C index.","volume":"6","author":"Tsuruta","year":"2006","journal-title":"BMC Med Inform Decis Mak"},{"key":"R18-11-20250124","doi-asserted-by":"crossref","first-page":"25842590","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood highrisk hepatoblastoma with doseintensive multiagent chemotherapy and surgery: final results of the SIOPEL3HR study.","volume":"28","author":"Zsiros","year":"2010","journal-title":"J Clin Oncol"},{"key":"R19-11-20250124","doi-asserted-by":"crossref","first-page":"818821","DOI":"10.1002\/pbc.24217","article-title":"Hepatoblastoma clinical research: lessons learned and future challenges.","volume":"59","author":"Perilongo","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R20-11-20250124","first-page":"12931302","article-title":"Liver transplantation in the management of unresectable hepatoblastoma in children.","volume":"4","author":"Meyers","year":"2012","journal-title":"Front Biosci (Elite Ed)"},{"key":"R21-11-20250124","doi-asserted-by":"crossref","first-page":"19731981","DOI":"10.1016\/j.jpedsurg.2008.05.031","article-title":"Survival after liver transplantation for hepatoblastoma: a 2center experience.","volume":"43","author":"Browne","year":"2008","journal-title":"J Pediatr Surg"},{"key":"R22-11-20250124","doi-asserted-by":"crossref","first-page":"240245","DOI":"10.1053\/jpsu.2002.30264","article-title":"Strategy for hepatoblastoma management: transplant versus nontransplant surgery.","volume":"37","author":"Pimpalwar","year":"2002","journal-title":"J Pediatr Surg"},{"key":"R23-11-20250124","doi-asserted-by":"crossref","first-page":"19761983","DOI":"10.1002\/cncr.25722","article-title":"Successful nontransplant resection of POSTTEXT III and IV hepatoblastoma.","volume":"117","author":"Lautz","year":"2011","journal-title":"Cancer"},{"key":"R25-11-20250124","doi-asserted-by":"crossref","first-page":"593599","DOI":"10.1002\/(SICI)1097-0215(19971219)74:6<593::AID-IJC6>3.0.CO;2-P","article-title":"Prognostic factors and staging systems in childhood hepatoblastoma.","volume":"74","author":"von Schweinitz","year":"1997","journal-title":"Int J Cancer"},{"key":"R26-11-20250124","doi-asserted-by":"crossref","first-page":"15431549","DOI":"10.1016\/j.ejca.2011.12.011","article-title":"Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.","volume":"48","author":"Maibach","year":"2012","journal-title":"Eur J Cancer"},{"key":"R27-11-20250124","doi-asserted-by":"crossref","first-page":"150159","DOI":"10.1016\/j.surg.2012.11.006","article-title":"Analysis of national and singlecenter incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities.","volume":"153","author":"Cruz","year":"2013","journal-title":"Surgery"},{"key":"R28-11-20250124","doi-asserted-by":"crossref","first-page":"795804","DOI":"10.1016\/S0022-3476(00)44469-0","article-title":"Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence.","volume":"136","author":"Reyes","year":"2000","journal-title":"J Pediatr"},{"key":"R29-11-20250124","doi-asserted-by":"crossref","first-page":"11111120","DOI":"10.1002\/cncr.10282","article-title":"Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.","volume":"94","author":"Schnater","year":"2002","journal-title":"Cancer"},{"key":"R31-11-20250124","doi-asserted-by":"crossref","first-page":"24422450","DOI":"10.1016\/j.ejca.2011.12.032","article-title":"Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in highrisk patients.","volume":"48","author":"Wagner","year":"2012","journal-title":"Eur J Cancer"},{"key":"R32-11-20250124","doi-asserted-by":"crossref","first-page":"34563464","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastomaa phase II trial of the Childhood Liver Tumour Strategy Group (SIOPEL).","volume":"48","author":"Zsiros","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23803","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201403000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:31:37Z","timestamp":1737739897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201403000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23803","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}